SAUNDERS BRENT L 4

What Happened
Brent L. Saunders, a director of ARS Pharmaceuticals, was granted a derivative award for 30,000 shares on June 24, 2026. The Form 4 reports an acquisition price of $0.00 (a non‑cash award), so there was no cash paid at grant. This was an award/compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26.
• Transaction type/code: Grant / Award (Form 4 code A), reported as a derivative security.
• Amount: 30,000 shares (derivative); Price per share at grant: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The award will vest in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting (date not yet set).
• Filing timeliness: Filed two days after the transaction date (appears to meet the standard two-business-day Form 4 requirement).

Context
This is a typical director compensation award (time‑based vesting) and not an exercise or open‑market purchase/sale. Derivative grants like this generally vest over time and do not involve immediate cash changing hands.